Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,512
datasets available to search
ShareScore release 0.7.1
Dataset results
6,512 results for “clinical trial”
CONSORT flow diagram for The assessment of educational and supportive care to the infertile females undergoes In Vitro Fertilization procedure by clinical pharmacist: a randomized clinical trial
<p><strong>The assessment of educational and supportive care to the infertile females undergoes In Vitro Fertilization procedure by </strong>a <strong>clinical pharmacist: a randomized clinical trial</strong>.</p>
(Extended Data) Amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial
<p>These extended data accompany the manuscript: Targeted Amplicon deep sequencing of ama1 and mdr1 to track within-host <em>P. falciparum</em> diversity throughout treatment in a clinical drug trial</p> <p><strong>Table S1: Concentration ratios and resulting parasitemia in artificial dna mixtures of P. falciparum Lab Isolates 3D7 and Dd2.</strong> This table presents the parasitemia for the artificial mixtures of P. falciparum lab isolates 3D7 and Dd2. Each mixture was prepared at varying ratios of 3D7 to Dd2, starting from equal proportions to a complete presence of only 3D7. The original concentration of each isolate was approximately 50,000 parasites per microliter (pf/μl), and the table displays the proportion of each strain in the mixture and the resulting total parasitemia concentration.</p> <p><strong>Table S2. List of PCR and deep sequencing primers.</strong> This table shows the list of forward and reverse primers used for deep sequencing. In boldface are the MID tags, while in the regular face are the forward primers</p> <p><strong>Table S3. The relative frequencies of each ama1 variant and the number of samples with each variant.</strong> The relative frequencies (%) of the 33 AMA1 variants in pre-and post-treatment samples (n = 330) are shown as a 33 amino acid sequence. The frequencies were calculated by dividing the number of reads of each microhaplotype by the total number of reads obtained per sample (116,187,131).</p> <p><strong>Table S4. Distribution of microhaplotypes among samples.</strong> This table shows the occurrence of microhaplotypes across all participants, both with monoclonal and multiclonal ama1 infections. It presents the ama1 clonality – monoclonal or multiclonal (column 1) - participant IDs (column 2), microhaplotype IDs (column 3), and the relative frequencies of these microhaplotypes across timepoints from 0 to 1008 hours (day 42) (column 3). Dashes represent time points where microhaplotypes were missing or were not detected.</p> <p><strong>Table S5. Distribution of rare microhaplotypes among samples.</strong> This table shows the occurrence of rare microhaplotypes in various samples. It presents participant IDs (column 1), microhaplotype IDs (column 2), and the relative frequencies of these microhaplotypes across time points from 0 to 1008 hours (day 42) (column 3). Samples containing rare microhaplotypes - specifically from PID10, PID32, PID38, PID40, PID49, PID60, PID63, and PID65 - are shown in orange, along with the corresponding rare microhaplotypes and their time points of occurrence. Furthermore, participants are categorised by shared microhaplotypes to indicate instances of rarity and commonality. Except for one microhaplotype unique to PID30, rare microhaplotypes were detected in several samples, frequently exceeding a 5% relative frequency. Dashes represent time points where microhaplotypes were missing or were not detected.</p> <p><strong>Table S6. The parasitemia levels associated with each ama1 microhaplotype per timepoint.</strong> This table shows the parasitemia for each ama1 microhaplotype per timepoint and each participant. “Patient ID” represents the patient ID, “AMA1 COI at 0h” represents the complexity of infection (COI) for each participant at baseline, based on ama1 while subsequent columns represent the parasitemia for each ama1 microhaplotype from timepoint 0h to 1008h. Parasitemia was back-calculated using the COI and total parasitemia for each time point. For time points with a COI > 1, parasitemia for the respective ama1 microhaplotypes are separated by commas, cells in red indicate timepoints without sequencing data (ND = not determined). In contrast, cells in grey indicate time points where microhaplotypes were detected below 10 parasites/μl, hence at risk of falling below the sampling limit.</p> <p><strong>Figure S1. Performance of AmpSeq in the sequencing controls.</strong> Six aliquots were prepared for each control set to ensure sufficient control data in case of PCR or sequencing failure. The median read depth in the lab controls was 5,658 (range 4,310 – 12,603) and 704 (291 – 1,676). The x-axis represents the aliquot identifier across the five mixtures, starting from 1 to 6, while the y-axis represents the proportions of each variant across all aliquots. For ama1 (A), two variants (3D7 and Dd2) were detected, whereas in mdr1 (B), two variants were detected YY, FY and NY following amplification of Dd2 Copy I, Dd2 Copy II and 3D7, respectively. For ama1, sequencing failed for aliquot 6 of control set 1, while for mdr1, sequencing failed for aliquot 2 and 6 of control set 3, aliquots 1 and 6 of control set 4 and aliquots 1 and 5 of control set 5. Under the mdr1 control set 4, the Dd2 copy II (86F, 184Y) was not identified, possibly due to having very low concentrations that were not picked up in this aliquot. Based on our control mixtures, the minimum variant frequency we could detect was 5%.</p> <p><strong>Figure S2. Heatmaps of the successfully PCR amplified and sequenced samples for ama1 (A) and mdr1 (B).</strong> The rows represent the study participants, while the columns represent time in hours. Successfully sequenced samples are shown in blue, those that failed PCR are shown in red and those that failed sequencing are in black. The timepoint “ Rec” represents unscheduled visits where a recurrent sample was collected. The unshaded areas with "-" are time points where samples were not collected. For each time point, the number of samples successfully sequenced (n Successful) is indicated in the last row of each panel. The table in panel C shows the groupings of samples based on parasitemia, high (> 5,000), moderate (100-5,000) and low (< 100 parasites per microlitre). Many samples collected between 0h-12h had high parasitemia, samples collected between 18h–30h had moderate parasitemia, while samples collected after 30h were primarily of low parasitemia.</p> <p><strong>Figure S3. The mean complexity of infection (COI) by AMA1 throughout treatment.</strong> The mean COI (red diamonds) appeared to be stable (between 1.5 - 2) from baseline (0h) up to 72h and thereafter fluctuated due to the small sample sizes (<5) in the post-treatment samples. The black dots represent the COI per sample.</p> <p> </p>
Data for article "Personal approach for cancer treatment: a meta-analysis of Phase II Clinical trials"
<p>We conducted systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients who underwent personalized genomics-based versus non-personalized treatment in oncology. The PubMed searches detected 803 studies based on phase II clinical trials’ results published from 2010 to 2021. We selected 50 studies, having 81 arms and 6536 patients for the analysis. We compared Response Rate (RR), medians and 1-year rates of Overall Survival (OS) and Progression-Free Survival (PFS) between genomics-based personalized and non-personalized arms. This repository contains final dataset (Dataset file) and t<span lang="EN-US">he information on 803 studies identified in the literature search (803 studies description file)</span>. </p> <p>The searches, study selection, data extraction and synthesis were performed in accordance to PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines. The research protocol was registered in PROSPERO (International prospective register of systematic reviews, <a href="https://www.crd.york.ac.uk/PROSPERO" rel="nofollow">https://www.crd.york.ac.uk/PROSPERO</a>), record ID CRD42024504021. </p> <p>We performed proportional meta-analysis using the RStudio program, utilizing the R programming language and packages "meta", "metafor," and "tidyverse", the code is available at github: https://github.com/MikhailPot/PreciseOnco_meta-analysis </p>
Capacitive resistive monopolar radiofrequency at 448 kHz plus exercise versus exercise alone for subacromial pain: Randomized sham-controlled clinical trial.
<p>Objective: To investigate the effectiveness of thermal and sub-thermal capacitive resistive 448kHz monopolar radiofrequency (CRMRF) plus exercise compared to Sham CRMRF plus exercise on pain, functionality, and quality of life in patients with subacromial pain.</p> <p>Material and methods: A randomized sham-controlled double blind clinical trial was designed. Eighty-one participants with subacromial pain were enrolled and randomly assigned to three intervention groups (Thermal CRMRF, Sub-thermal CRMRF, and Sham CRMRF). The main outcomes variables were for pain: visual analogic scale (VAS) and pressure pain threshold, for functionality: shoulder pain and disability index (SPADI) and Quick- Disabilities of the Arm, Shoulder and Hand (Quick-DASH) and for quality of life: European Quality of Live Five Dimensions (EQ-5D). Variables were measured at baseline, post-intervention, and at one-month and three months follow-ups. An intention-to-treat analysis was realized.</p> <p>Results: All three groups statistically (p<0.01) and clinically significantly improved pain (VAS) and functionality (SPADI) respect to baseline at post-intervention and follow-up periods. The improvement in Quick-DASH outcome respect to baseline at one month follow-up was clinically relevant only in the thermal CRMRF group (-16.8 points; CI95% -27.3 to -6.3). Thermal-CRMRF group showed a greater effect on Quick-DASH at one month follow-up (-14.1 points, CI95% -28.1 to -0.1) compared with Sham-CRMRF group. EQ-5D measure at one month follow-up only improved in thermal-CRMRF group (0.12 points; CI95% 0.01 to 0.23). Only thermal-CRMRF group improved the pressure pain threshold outcome (0.42 kg/cm<sup>2 </sup>CI95% 0.05 to 0.79) at post-treatment.</p>
Clinical Trial Subject Management System (CTSMS)
<p>CTSMS is mainly composed of three stages: operational management pre-configuration, subject recruitment, and subject visit management. The features included in the operational management pre-configuration stage include study participant assignments, protocol configuration, e-CRF form design, rule configuration, and global control over the access rights and visitation rules of subjects under the study project. The main features of the subject recruitment stage of the system include subject recruitment, subject violation verification, subject lists, and subject global labeling, to realize the registration of subjects under the corresponding study project, status labeling, and visualization.</p>
Remodeling dental anatomy vs sham therapy for chronic temporomandibular disorders: A placebo-controlled randomized clinical trial
<div><em>Background</em></div> <div>Evidence regarding the etiology or effective treatments for chronic orofacial pain, the majority diagnosed as temporomandibular disorder (TMD), is limited.</div> <div> </div> <div><em>Purpose</em></div> <div>To investigate whether occlusal equilibration therapy (ET) and decreasing the (higher) angle of the lateral guidance on the nonworking-side leads to a reduction in chronic TMDs intensity.</div> <div> </div> <div><em>Methods</em></div> <div>It was conducted a randomized, explanatory, single blind with blinded assessment, placebo-controlled trial with strong protection against bias involving patients with chronic TMDs. Participants were randomly assigned to receive equilibration therapy or sham therapy. ET in this study consisted of minimal invasive occlusal remodeling to obtain balanced occlusion with reduction of the steeper angle of lateral mandibular movement with respect to the Frankfort plane. The primary outcome was a change in the pain intensity score (on a 0–10 point scale, with 0 indicating no pain and 10 the worst possible pain) at month 6. Secondary outcomes include maximum unassisted mouth opening and psychological distress.</div> <div> </div> <div><em>Results</em></div> <div>A total of 77 participants underwent randomization, 39 of whom received ET and 38 sham therapy. The trial was stopped early for efficacy, according to preestablished rules when 67 participants (n = 34, n = 33, respectively) had completed the analysis. At month 6, the mean unadjusted pain intensity score was 2.1 in the ET and 3.6 in the sham therapy group (adjusted mean difference, −1.54; 95% confidence interval [CI] −0.5 to −2.6; P = 0.004; ANCOVA model). The mean increase in maximum unassisted mouth opening (main secondary outcome) was significantly higher in the real therapy group (adjusted mean difference 3.1 mm, 95% CI 0.5–5.7, p = 0.02).</div> <div> </div> <div><em>Conclusion</em></div> <div>ET significantly reduced the intensity of facial pain associated with chronic TMDs and increased maximum unassisted mouth opening, as compared with sham therapy, over the course of 6 months. There were no serious adverse events.</div>
CT-EBM-SP - Corpus of Clinical Trials for Evidence-Based-Medicine in Spanish
<p>A collection of 1200 texts (292 173 tokens) about clinical trials studies and clinical trials announcements in Spanish:</p> <p>- 500 abstracts from journals published under a Creative Commons license, e.g. available in PubMed or the Scientific Electronic Library Online (SciELO).<br> - 700 clinical trials announcements published in the European Clinical Trials Register and Repositorio Español de Estudios Clínicos.</p> <p>Texts were annotated with entities from the Unified Medical Language System semantic groups: anatomy (ANAT), pharmacological and chemical substances (CHEM), pathologies (DISO), and lab tests, diagnostic or therapeutic procedures (PROC). 46 699 entities were annotated (13.98% are nested entities). 10% of the corpus was doubly annotated, and inter-annotator agreement (IAA) achieved a mean F-measure of 85.65% (±4.79, strict match) and a mean F-measure of 93.94% (±3.31, relaxed match). </p> <p>The corpus is freely distributed for research and educational purposes under a Creative Commons Non-Commercial Attribution (CC-BY-NC-A) License.</p>
EXTRACT-NOAC randomized clinical trial Dataset
<p>This database concerns a randomized clinical trial, called the EXTRACT-NOAC trial. The title of the trial is 'Tranexamic acid and bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants'. The aim of the trial was to evaluate the efficacy of tranexamic acid mouthwash to reduce bleeding after dental extraction in patients on non-vitamin K oral anticoagulants. </p>
WikiProject Clinical Trials - WikiConference North America 2021 presentation
<p>Lane Rasberry presents "WikiProject Clinical Trials, Wikipedia for Research" at WikiConference North America 8 October 2021. Included here is a video recording of the live presentation and the slides presented.</p> <ul> <li>conference page: <a href="https://wikiconference.org/wiki/Submissions:2021/WikiProject_Clinical_Trials,_Wikipedia_for_Research">https://wikiconference.org/wiki/Submissions:2021/WikiProject_Clinical_Trials,_Wikipedia_for_Research</a></li> <li>slides archive: <a href="https://commons.wikimedia.org/wiki/File:WikiProject_Clinical_Trials.pdf">https://commons.wikimedia.org/wiki/File:WikiProject_Clinical_Trials.pdf</a></li> <li>watch video: <a href="https://www.youtube.com/watch?v=HR35orgEmlA">https://www.youtube.com/watch?v=HR35orgEmlA</a></li> </ul> <p>Thanks</p> <ul> <li><a href="https://commons.wikimedia.org/wiki/File:Noun_clinical_benchmarking_1958245.svg">https://commons.wikimedia.org/wiki/File:Noun_clinical_benchmarking_1958245.svg</a> by Bold Yellow</li> <li><a href="https://commons.wikimedia.org/wiki/File:Wikipe-tan_full_length.svg">https://commons.wikimedia.org/wiki/File:Wikipe-tan_full_length.svg</a> by Kasuga</li> </ul>
WikiProject Clinical Trials for multilingual access to information
<p>Watch at <a href="https://www.youtube.com/watch?v=uJbn0dPqAE8">https://www.youtube.com/watch?v=uJbn0dPqAE8</a></p> <p>WikiProject Clinical Trials is a wiki community project to increase access to medical research metadata. Check it out at <a href="https://www.wikidata.org/wiki/Wikidata:WikiProject_Clinical_Trials">https://www.wikidata.org/wiki/Wikidata:WikiProject_Clinical_Trials</a></p> <p>Here I argue that everyone has a right to access medical research metadata and that for public interest, we need to translate basic information from trials into many languages. I piloted this process in Wikidata.</p>
FAIR and Open multilingual clinical trials in Wikidata and Wikipedia
<p>"FAIR and Open multilingual clinical trials in Wikidata and Wikipedia" was a December 2021 presentation by Lane Rasberry and Cherrie Kwok. It was made at the conference "Understanding Wikipedia’s Dark Matter - Translation and Multilingual Practice in the World'’s Largest Online Encyclopaedia" hosted by the Centre for Translation and the Department of Translation, Interpreting and Intercultural Studies, both at Hong Kong Baptist University.</p> <ul> <li>conference page <a href="https://ctn.hkbu.edu.hk/wikiconf2021/">https://ctn.hkbu.edu.hk/wikiconf2021/</a></li> <li>watch video <a href="https://www.youtube.com/watch?v=5yRhCENeezQ">https://www.youtube.com/watch?v=5yRhCENeezQ</a></li> <li>slides archive <a href="https://commons.wikimedia.org/wiki/File:FAIR_and_Open_multilingual_clinical_trials_in_Wikidata_and_Wikipedia.pdf">https://commons.wikimedia.org/wiki/File:FAIR_and_Open_multilingual_clinical_trials_in_Wikidata_and_Wikipedia.pdf</a></li> </ul> <p> </p> <p> </p> <p> </p>
A randomized clinical trial to compare P. falciparum gametocytaemia and infectivity following blood-stage or mosquito bite induced controlled malaria infection
<p>For malaria elimination efforts, it is important to better understand parasite transmission to mosquitoes and to develop models to allow early clinical evaluation of transmission-blocking interventions. We previously described a Controlled Human Malaria Infection protocol for induction of gametocytemia in malaria naïve volunteers by mosquito bite (CHMI-trans) (Reuling et al., 2018). Here, we compared gametocyte production and infectivity in the CHMI-trans model after bites of <em>Plasmodium falciparum (Pf)- </em>infected mosquitoes to that after intravenous administration of <em>Pf-</em>infected-erythrocytes. Volunteers received (sub) curative treatments with gametocyte-permissive piperaquine or sulfadoxine-pyrimethamine. Blood-stage inoculation induced considerably higher gametocyte densities compared to mosquito bitesthat was predicted by <em>Pf</em>AP2-G transcripts indicative of gametocyte commitment, and resulted in <em>Pf</em>-positive mosquito infections in 9/12 volunteers versus 0/12 volunteers after mosquito bite inoculation. Current findings firmly establish the CHMI-trans with intravenous administration of asexual parasites as a model for early clinical evaluation of interventions that aim to interrupt <em>Pf</em>-transmission.</p>
Single-cell expression and TCR data from CD19-specific CAR T cells in a phase I/II clinical trial
<p><span>By leveraging single-cell transcriptome and T cell receptor (TCR) sequencing, we aimed to track the transcriptional signatures of CAR T cell clonotypes throughout the course of treatment and furthermore identify molecular patterns leading to potent CAR T cell cytotoxicity. The data presented in this study encompass blood and bone marrow samples from patients ≤ 21 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) participating in the SJCAR19 phase I/II clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03573700">NCT03573700</a>). In brief, patients enrolled in the clinical trial received either 1 x 10^6 (dose level 1) or 3 x 10^6 (dose level 2) per kilogram of body weight following successful generation of autologous CAR T cell products and lymphodepleting chemotherapy. Peripheral blood was drawn from each participant every week until week 4 post-infusion, at week 6 or 8, and month 3 or 6 if feasible. At week 4 post-infusion, blood marrow was also collected from participants. Total T cells (CD3+) were sorted from each post-infusion sample, as well as the pre-infusion CAR T cell products, and processed through 10x Genomics' single-cell gene expression and V(D)J sequencing platform using the standard protocol. We identified a unique and unexpected transcriptional signature in a subset of pre-infusion CAR T cells that shared TCRs with post-infusion cytotoxic effector CAR T cells. Functional validation of cells with even a subset of these pre-effector markers demonstrated their immediate cytotoxic potential and resistance to exhaustion.</span></p>
Effect Of Pulsed Electromagnetic Field And Microwave Therapy On Pain And Physical Function In Older Adults With Knee Osteoarthritis: A Randomized Clinical Trial.
<p><strong><span>Background and purpose:</span></strong><span> </span><span>Pulsed electromagnetic field (PEMF) therapy and microwaves (MW) are two electrotherapy modalities that have shown to improve pain and function in patients with knee osteoarthritis (KOA). Nevertheless, the effectiveness of these therapies is controversial due to diversity in the application parameters and treatment protocols in these patients. The objective is to compare the effectiveness of active PEMF versus MW, as well as sham PEMF, in addressing pain and improving functionality for treating KOA.</span></p> <p><strong><span>Methods:</span></strong><span> </span><span>Double-blind, placebo-controlled, randomized clinical trial. Participants diagnosed with KOA were assigned to an intervention combining an exercise program with active PEMF, MW, or sham PEMF, delivered in three weekly sessions over four weeks. The main outcomes were pain, reported on a 0–10 cm visual analogue scale (VAS), and functionality, as evaluated with the Western Ontario and McMaster Universities Arthritis (WOMAC) questionnaire, and the Timed Up and Go test. The outcomes were measured at pre-intervention, immediately post-intervention, and one and four months after the intervention.</span></p>
The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis
<p>Meta data for the review entitled "The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis<strong>"</strong></p>
Predicting Publication of Clinical Trials Using Structured and Unstructured Data
<p>This dataset (N=76,950) links metadata from ClinicalTrials.gov (a registry of clinical trials) and MEDLINE (a bibliographic database of academic journal articles), and can be used to model whether a clinical trial will get published or not.</p>
Training, executive, attention and motor skills (TEAMS) training versus standard treatment for preschool children with attention deficit hyperactivity disorder: a randomised clinical trial
<p>This is the dataset used in the trial entitled Training, executive, attention and motor skills (TEAMS) training versus standard treatment for preschool children with attention deficit hyperactivity disorder, published in BMC Research Notes.</p>
Comparative Study of Intravenous Esmolol & Magnesium Sulphate in Attenuating Hemodynamic Response during Laryngoscopy & Endotracheal Intubation in Patients Undergoing Valvular Heart Surgery: a Randomised Clinical Trial
<p>The present study aimed to compare the effectiveness of esmolol & magnesium sulphate in attenuating the hemodynamic response<br> to endotracheal intubation and to note any signifi cant side effects caused by these drugs.<br> Background: Induction with endotracheal intubation in patients undergoing valvular heart replacement pose lot of hemodynamic<br> variations. Obtunding hemodynamic response which can be deleterious in such patients pose a challenge to the cardiac anaesthetist. We<br> hypothesized that using esmolol as compared to magnesium sulphate will attenuate the hemodynamic response during laryngoscopy &<br> endotracheal intubation in patients undergoing valvular heart replacement.<br> Methods: This was a double blind, randomised, single centre, interventional, prospective study. In this study 96 patients were divided<br> into two groups with 48 patients each (n = 48) by sealed enveloped method of randomisation. Group E received esmolol 1.5 mg/ kg i.v<br> and Group M received magnesium sulphate 50 mg/ kg i.v each diluted in normal saline to make up a volume of 50 ml & given via infusion<br> slowly over 5 minutes by a burette set. Hemodynamic parameters like Heart Rate (HR), Mean Arterial Pressure (MAP), Systolic Blood<br> Pressure (SBP), Diastolic Blood Pressure (DBP) at baseline, 5 minutes after premedication, just before intubation 3, 5, 10 & 15 minutes<br> post intubation were recorded. The last observation at the end of 15 minutes post intubation was considered as the end of study.<br> Results: All the enrolled patients were analyzed. The esmolol group showed a decrease in the H.R from baseline (86.13 ± 15.87)<br> as compared to magnesium sulphate (98.51 ± 16.81 with a 95% CI, 4.62-4.69, p value < 0.001) 5 minute after premedication. There was<br> statistically signifi cant difference in H.R between both groups 5 minutes after drug administration.<br> Conclusion: Administration of esmolol before intubation in valvular heart patients undergoing valve replacement surgery controls the<br> hemodynamic response much better as compared to magnesium sulphate.</p>
Dataset S2 - Viral metagenomics in the clinical realm: lessons learned from a Swiss-wide ring trial
<p>Dataset S2. FASTQ datasets for increment 2.</p> <p>Supplemental material of article "Viral metagenomics in the clinical realm: lessons learned from a Swiss-wide ring trial".</p>
Dataset S1 - Viral metagenomics in the clinical realm: lessons learned from a Swiss-wide ring trial
<p>Dataset S1. SIB common database.</p> <p>Supplementary material from article "Viral metagenomics in the clinical realm: lessons learned from a Swiss-wide ring trial".</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.